The FDA Approved Phathom Pharmaceuticals' Voquezna (Vonoprazan) 10 mg Tablets For Heartburn Associated With Non-erosive Gastroesophageal Reflux Disease In Adults, This Is The Third FDA Approval For Voquezna
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Phathom Pharmaceuticals' Voquezna (Vonoprazan) 10 mg tablets for treating heartburn associated with non-erosive gastroesophageal reflux disease in adults. This marks the third FDA approval for Voquezna.
July 18, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phathom Pharmaceuticals received FDA approval for Voquezna (Vonoprazan) 10 mg tablets for heartburn associated with non-erosive GERD in adults. This is the third FDA approval for Voquezna, potentially boosting the company's market position and revenue.
The FDA approval of Voquezna (Vonoprazan) 10 mg tablets for heartburn associated with non-erosive GERD in adults is a significant milestone for Phathom Pharmaceuticals. This is the third FDA approval for Voquezna, which could enhance the company's market position and drive revenue growth. The approval is likely to positively impact PHAT's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100